Traduction de «established medicines » (Néerlandais → Français) :

Exforge 222 171 30 33 653 475 37 37 Tekturna/Rasilez 113 83 36 42 305 202 51 53 Subtotal 1 818 1 718 6 7 5 435 5 076 7 6 Galvus 101 50 102 114 267 115 132 136 Lotrel 80 75 7 4 224 244 -8 -9 Total strategic products 1 999 1 843 8 10 5 926 5 435 9 8 Established medicines 264 320 -18 -17 836 997 -16 -17 Total 2 263 2 163 5 6 6 762 6 432 5 4
M USD M USD USD tcc M USD M USD USD tcc Médicaments hypotenseurs Diovan 1 483 1 464 1 2 4 477 4 399 2 1 Exforge 222 171 30 33 653 475 37 37 Rasilez/Tekturna 113 83 36 42 305 202 51 53 Sous-total 1 818 1 718 6 7 5 435 5 076 7 6 Galvus 101 50 102 114 267 115 132 136 Lotrel 80 75 7 4 224 244 -8 -9 Total produits stratégiques 1 999 1 843 8 10 5 926 5 435 9 8 Médicaments établis 264 320 -18 -17 836 997 -16 -17 Total 2 263 2 163 5 6 6 762 6 432 5 4

USD m USD m USD cc USD m USD m USD cc Neoral/Sandimmun 207 227 -9 -8 636 675 -6 -8 Reclast/Aclasta 143 125 14 15 408 325 26 25 Myfortic 122 93 31 30 330 256 29 25 Zortress/Certican 35 32 9 19 105 82 28 29 Ilaris 6 1 nm nm 16 1 nm nm Other 74 62 19 19 214 165 30 27 Total strategic products 587 540 9 10 1 709 1 504 14 12 Established medicines 237 249 -5 -6 661 706 -6 -9 Total 824 789 4 5 2 370 2 210 7 5 nm – not meaningful
M USD M USD USD tcc M USD M USD USD tcc Sandimmune/Néoral 207 227 -9 -8 636 675 -6 -8 Aclasta/Reclast 143 125 14 15 408 325 26 25 Myfortic 122 93 31 30 330 256 29 25 Certican/Zortress 35 32 9 19 105 82 28 29 Ilaris 6 1 ns ns 16 1 ns ns Autres 74 62 19 19 214 165 30 27 Total produits stratégiques 587 540 9 10 1 709 1 504 14 12 Médicaments établis 237 249 -5 -6 661 706 -6 -9 Total 824 789 4 5 2 370 2 210 7 5 ns: non significatif

USD m USD m USD cc USD m USD m USD cc Xolair 97 78 24 32 267 218 22 24 TOBI 70 76 -8 -5 207 219 -5 -5 Onbrez 8 0 nm nm 16 0 nm nm Other 0 -2 nm nm 0 -1 nm nm Total strategic products 175 152 15 20 490 436 12 13 Established medicines 37 40 -8 -4 126 136 -7 -9 Total 212 192 10 15 616 572 8 8 nm – not meaningful
M USD M USD USD tcc M USD M USD USD tcc Xolair 97 78 24 32 267 218 22 24 TOBI 70 76 -8 -5 207 219 -5 -5 Onbrez 8 0 ns ns 16 0 ns ns Autres 0 -2 ns ns 0 -1 ns ns Total produits stratégiques 175 152 15 20 490 436 12 13 Médicaments établis 37 40 -8 -4 126 136 -7 -9 Total 212 192 10 15 616 572 8 8 ns – non significatif

Q3 2010 Q3 2009 % change 9M 2010 9M 2009 % change USD m USD m USD cc USD m USD m USD cc Lucentis 398 335 19 22 1 139 858 33 30 Exelon/Exelon Patch 244 251 -3 0 747 687 9 8 Comtan/Stalevo 152 141 8 9 443 402 10 9 Extavia 26 14 86 102 84 26 nm nm Other 111 108 3 6 343 343 0 -1 Total strategic products 931 849 10 13 2 756 2 316 19 17 Established medicines 137 145 -6 -6 419 426 -2 -5 Total 1 068 994 7 10 3 175 2 742 16 14 nm – not meaningful
M USD M USD USD tcc M USD M USD USD tcc Lucentis 398 335 19 22 1 139 858 33 30 Exelon/Exelon Patch 244 251 -3 0 747 687 9 8 Stalevo/Comtan 152 141 8 9 443 402 10 9 Extavia 26 14 86 102 84 26 ns ns Autres 111 108 3 6 343 343 0 -1 Total produits 2 756 2 316 stratégiques 931 849 10 13 19 17 Médicaments établis 137 145 -6 -6 419 426 -2 -5 Total 1 068 994 7 10 3 175 2 742 16 14 ns: non significatif

Exforge 222 171 30 33 Tekturna/Rasilez 113 83 36 42 Subtotal 1 818 1 718 6 7 Galvus 101 50 102 114 Lotrel 80 75 7 4 Total strategic franchise products 1 999 1 843 8 10 Established medicines (including Lescol) 264 320 -18 -17 Total Cardiovascular and Metabolism products 2 263 2 163 5 6
Exforge 222 171 30 33 Rasilez/Tekturna 113 83 36 42 Sous-total 1 818 1 718 6 7 Galvus 101 50 102 114 Lotrel 80 75 7 4 Total produits stratégiques 1 999 1 843 8 10 Médicaments établis (Lescol inclus) 264 320 -18 -17 Total produits cardiovasculaires et métaboliques 2 263 2 163 5 6

Exelon/Exelon Patch 244 251 -3 0 Comtan/Stalevo 152 141 8 9 Extavia 26 14 86 102 Other 111 108 3 6 Total strategic franchise products 931 849 10 13 Established medicines 137 145 -6 -6 Total Neuroscience and Ophthalmics products 1 068 994 7 10
Exelon/Exelon Patch 244 251 -3 0 Comtan/Stalevo 152 141 8 9 Extavia 26 14 86 102 Autres 111 108 3 6 Total produits stratégiques 931 849 10 13 Médicaments établis 137 145 -6 -6 Total produits neurologiques et ophtalmologiques 1 068 994 7 10

TOBI 70 76 -8 -5 Onbrez 8 0 nm nm Other -2 nm nm Total strategic franchise products 175 152 15 20 Established medicines 37 40 -8 -4 Total Respiratory products 212 192 10 15
TOBI 70 76 -8 -5 Onbrez 8 0 ns ns Autres -2 ns ns Total produits stratégiques 175 152 15 20 Médicaments établis 37 40 -8 -4 Total produits Pneumologie 212 192 10 15

Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products Royal decrees of 25 February 2007 on the composition and working method of the committees of the Federal Agency for Medicines and Health Products Royal decree of 20 December 2007 determining the date of establishment of the Scientific Committee, namely 1 February 2008 Royal decree of 28 January 2008 on the concrete composition of the Consultative Committee Ministerial decree of 11 January 2007 on the composition and appointment of the members of the executive board of the Federal Agency for Medicines and Health Products
Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products Royal decrees of 25 February 2007 on the composition and working method of the committees of the Federal Agency for Medicines and Health Products Royal decree of 20 December 2007 determining the date of establishment of the Scientific Committee, namely 1 February 2008 Royal decree of 28 January 2008 on the concrete composition of the Consultative Committee Ministerial decree of 11 January 2007 on the composition and appointment of the members of the executive board of the Federal Agency for Medicines and Health Products

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

Advisory commission which is consulted e.g. in cases of non-availability of medicines Commission for the approval of institutions assigning preliminary approvals for scientific events Commission for the establishment of retail pharmacies and chambers of appeal (Frenchspeaking chamber and Dutch-speaking chamber) Commission for the recognition of pharmacists-clinical biologists Commission for the supervision of advertising for medicines for human use Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines Pharmacopoeia commission
Advisory commission which is consulted e.g. in cases of non-availability of medicines Commission for the approval of institutions assigning preliminary approvals for scientific events Commission for the establishment of retail pharmacies and chambers of appeal (Frenchspeaking chamber and Dutch-speaking chamber) Commission for the recognition of pharmacists-clinical biologists Commission for the supervision of advertising for medicines for human use Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines Pharmacopoeia commission